|
Listen to article
|
By the midpoint of this century, the global population aged 65 and older is projected to more than double, significantly increasing the prevalence of age-related conditions such as heart disease, dementia, cancer, and vision disorders (Błasiak et al., 2021). Despite decades of medical advancements aimed at treating these diseases individually, their collective impact remains profound, highlighting the need for a more holistic approach to address aging itself, the common root cause.
In response, the ever evolving field of geroscience integrates biology, medicine, and biotechnology to target fundamental mechanisms underlying aging. Instead of isolated disease treatments, geroscience aims to enhance healthspan, the period of life spent free from significant illness—by modulating the biological processes of aging at their core (Papadopoli et al., 2019).
One prominent area of investigation involves targeting cellular senescence—where aged cells accumulate and contribute significantly to chronic inflammation and tissue degradation (Saoudaoui et al., 2021). Research demonstrates that inhibiting the mechanistic target of rapamycin (mTOR) pathway is effective in reducing cellular senescence and enhancing clearance of these aged cells, thereby improving overall tissue health and function (Kucheryavenko et al., 2019; Hambright et al., 2020). Rapamycin, a potent inhibitor of mTOR, has shown promising results, protecting cells against senescence by activating autophagy—a process that removes damaged cellular components and rejuvenates cell function (Nie et al., 2021; Kumar et al., 2022).
Additionally, researchers are investigating the relationship between mTOR signaling and telomere biology, another critical factor in aging. Telomeres, protective structures at the ends of chromosomes, naturally shorten with age, contributing to cellular aging and increased susceptibility to disease. Recent studies reveal that mTOR inhibition can positively impact telomere maintenance, providing a potential dual benefit of lifespan extension and disease reduction (Ferrara-Romeo et al., 2020).
However, extending telomeres through telomerase activation involves complex trade-offs, notably increased cancer risks, requiring careful therapeutic balancing (Błasiak et al., 2021). Thus, interventions aimed at aging reversal demand rigorous safety evaluations to minimize unintended consequences.
Another innovative direction involves DNA methylation patterns—known as epigenetic clocks—that accurately predict biological aging and associated health outcomes (Field, 2019; Horvath et al., 2019). These epigenetic markers provide reliable measures for evaluating the effectiveness of anti-aging interventions, including mTOR inhibitors, allowing scientists to quantify rejuvenation effects objectively (Vidović et al., 2023).
Moreover, cutting-edge strategies like DNA nanoplatform-based delivery systems have been developed for precisely targeting the mTOR complex, representing an advanced therapeutic approach to age-related diseases (Yue et al., 2024). Animal model studies, including recent findings in Drosophila, suggest that modulation of mTOR signaling could offer sex-specific regulation of lifespan and organ homeostasis, further emphasizing its potential as a universal aging therapy (Regan et al., 2021).
Read also: Prof. Nze Advocates Accountability Through Journalism
While these breakthroughs provide promising pathways for age reversal, substantial challenges remain. Powerful therapies capable of altering fundamental aging processes require thorough long-term clinical trials to ensure safety, efficacy, and proper dosing (Blagosklonny, 2021; Blagosklonny, 2022). Moreover, the initially high costs of these therapies present significant accessibility concerns, especially in resource-limited regions, underscoring broader ethical and equity considerations.
Furthermore, extending healthy human lifespan significantly impacts healthcare infrastructure, economic sustainability, and intergenerational dynamics. Such transformative demographic shifts necessitate careful societal and ethical consideration, alongside proactive policy planning.
Throughout the “Turning Back the Clock” series, each article will objectively explore these transformative scientific advancements, providing balanced discussions grounded in rigorous evidence and clear explanations. Blending scientific data with relatable human narratives, this series aims to foster an informed understanding of how modern science is redefining aging—not simply as inevitable decline, but as a modifiable aspect of human health, vitality, and well-being.
– Prof. MarkAnthony Nze
Academic Director/Chair of the Academic Board, New York Learning Hub
References
Blagosklonny, M.V. (2021) ‘Rapamycin, mTOR, and gerostatics: A promising approach to slow aging’, Aging, 13(13), pp. 16364–16365.
Blagosklonny, M.V. (2022) ‘Rapamycin for longevity: opinion article’, Aging, 14(1), pp. 361–365.
Błasiak, J., Kucharska, E. and Pawlowska, E. (2021) ‘Telomerase in the retina: the aging eye and its diseases’, International Journal of Molecular Sciences, 22(6), p. 2798.
Ferrara-Romeo, I. et al. (2020) ‘The mTOR pathway is a key regulator of the aging process through its effects on telomere biology’, Nature Communications, 11, pp. 1–12.
Field, A.E. (2019) ‘DNA methylation clocks in aging: categories, causes, and consequences’, Molecular Cell, 71(6), pp. 882–895.
Hambright, H.G. et al. (2020) ‘Rapamycin protects against senescence by modulation of mTOR and autophagy pathways in aged cells’, Aging Cell, 19(9), e13120.
Horvath, S. et al. (2019) ‘Epigenetic clock and methylation studies in aging: Current concepts and future directions’, Nature Reviews Genetics, 20(7), pp. 371–382.
Kucheryavenko, O. et al. (2019) ‘Inhibition of mTORC1 signaling promotes clearance of senescent cells’, Nature Aging, 1(4), pp. 272–283.
Kumar, R. et al. (2022) ‘Rejuvenation of senescent cells using low-frequency ultrasound and rapamycin’, Nature Biomedical Engineering, 6, pp. 287–299.
Nie, M. et al. (2021) ‘Rapamycin induces autophagy and reverses senescence in tendon stem/progenitor cells’, Stem Cells International, 2021, Article ID 9933906.
Papadopoli, D. et al. (2019) ‘mTOR as a central regulator of lifespan and aging’, Mechanisms of Ageing and Development, 180, pp. 1–10.
Regan, J.C. et al. (2021) ‘Sex-specific regulation of intestinal homeostasis and lifespan by mTOR signaling in Drosophila’, Aging Cell, 20(1), e13265.
Saoudaoui, A. et al. (2021) ‘Role of mTOR in regulating cellular senescence and age-associated diseases’, Cells, 10(5), p. 1155.
Vidović, D. et al. (2023) ‘An AI-predicted mTOR inhibitor promotes longevity and shows anti-cancer activity in human cells’, Aging, 15(2), pp. 742–759.
Yue, L. et al. (2024) ‘Targeting mTORC1 using DNA nanoplatform for age-related therapy’, Nano Today, 48, p. 101721.
